QQ客服 官方微博 反馈留言

浏览/检索结果: 共4条，第1-4条 帮助 限定条件 专题：中国医学科学院 北京协和医学院    第一署名单位    第一作者单位    通讯作者单位     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择作者升序作者降序题名升序题名降序发表日期升序发表日期降序提交时间升序提交时间降序 CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase I 期刊论文 2019, 卷号: 39, 期号: 1, 页码: 28 作者:  Shi, Yuankai;  Li, Jin;  Xu, Jianming;  Sun, Yan;  Wang, Liwei 收藏  |  浏览/下载：43/0  |  提交时间：2020/01/03 CMAB009  Cetuximab  Irinotecan  Second-line  mCRC  EGFR  KRAS  Immunogenicity  Fluoropyrimidine  Oxaliplatin failure   Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study 期刊论文 2019, 卷号: 257, 期号: 3, 页码: 529-541 作者:  Li, Xiaoxin;  Dai, Hong;  Li, Xiaorong;  Han, Mei;  Li, Jun 收藏  |  浏览/下载：172/0  |  提交时间：2020/01/03 Anti-vascular endothelial growth factor  Diabetic macular edema  Pro re nata  Ranibizumab   A phase III trial (ZJBI0009): CMABOO9 plus irinotecan versus irinotecan alone as second-line treatment after fluoropyrimidine and oxaliplatin failure in wild-type K-ras metastatic colorectal cancer patients. 会议论文 JOURNAL OF CLINICAL ONCOLOGY, 2017-05-20 作者:  Shi, Yuankai;  Li, Jin;  Xu, Jianming;  Cheng, Ying;  Liu, Wei 收藏  |  浏览/下载：2/0  |  提交时间：2020/01/04 A phase III trial (ZJBI0009): CMABOO9 plus irinotecan versus irinotecan alone as second-line treatment after fluoropyrimidine and oxaliplatin failure in wild-type K-ras metastatic colorectal cancer patients. 期刊论文 2017, 卷号: 35 作者:  Shi, Yuankai;  Li, Jin;  Xu, Jianming;  Cheng, Ying;  Liu, Wei 收藏  |  浏览/下载：2/0  |  提交时间：2020/01/04